RSV Prevention in Infants: Promising Products, But at What Cost?
- Sean O'Leary
Access Resources
About
This commentary is related to two studies on the cost-effectiveness of maternal vaccination and nirsevimab for infants for the prevention of respiratory syncytial virus (RSV). The author states Hutton et al's studies show that maternal vaccination with RSVpreF and nirsevimab can greatly reduce the impact of RSV. However, the high costs mean careful management is needed by healthcare providers to make them viable. Successful broad delivery of these vaccines could lead to significant reductions in RSV-related burdens.
Tags
More like this
The information provided on this website is for educational purposes only. It does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.